复星医药:从千亿市值蒸发到创新药商业化困局的“双刃剑”博弈

中金在线
29 Jul

复星医药 (SH600196)正站在转型的十字路口。作为 中国医药 行业的龙头企业,其近年的经营表现与发展路径引发了市场广泛关注。从财务数据看,公司2024年营业收入连续两年下滑,净利润却因非经常性损益和财务策略调整实现增长;从战略层面看,“创新+国际化”转型初见成效,但高比例研发资本化、债务压力及外部政策环境等多重风险交织,令其发展之路充满不确定性。2024年,复星医药全年营业收入410.67...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10